Summary
IDEXX Laboratories, Inc. reported solid financial results for the nine months ended September 30, 2014, with total revenue growing by 10.8% year-over-year to $1.13 billion. This growth was primarily driven by the Companion Animal Group (CAG) segment, which saw an 11.3% increase in recurring diagnostic revenue. The company also demonstrated effective cost management, leading to a 9.7% increase in total operating income despite higher operating expenses, including significant investments in transitioning to an all-direct sales strategy in the U.S. Financially, IDEXX maintained a healthy cash position, with cash and cash equivalents increasing to $292.7 million. The company also successfully managed its debt, refinancing its credit facility and issuing new senior notes to support its growth initiatives. However, investors should note the anticipated impact of the U.S. all-direct sales transition, which is expected to result in a revenue and operating profit reduction of $18 million to $23 million and $15 million to $19 million, respectively, in the fourth quarter of 2014, as distributor inventories are drawn down.
Financial Highlights
52 data points| Revenue | $383.52M |
| Cost of Revenue | $170.19M |
| Gross Profit | $213.34M |
| R&D Expenses | $24.85M |
| Operating Income | $72.19M |
| Interest Expense | $4.29M |
| Net Income | $52.14M |
| EPS (Basic) | $0.52 |
| EPS (Diluted) | $0.52 |
| Shares Outstanding (Basic) | 99.49M |
| Shares Outstanding (Diluted) | 100.80M |
Key Highlights
- 1Total revenue increased by 10.8% to $1.13 billion for the nine months ended September 30, 2014, compared to the prior year period.
- 2The Companion Animal Group (CAG) segment remains the primary growth driver, with recurring diagnostic revenue up 11.3% year-over-year for the nine months.
- 3Operating income increased by 9.7% to $225.5 million for the nine months ended September 30, 2014.
- 4The company significantly increased its share repurchases, spending $469.0 million in the nine-month period, up from $282.9 million in the prior year.
- 5IDEXX completed a refinancing of its revolving credit facility, increasing it to $700 million, and issued $350 million in senior notes throughout 2014.
- 6The company is transitioning to an all-direct sales strategy in the U.S. for certain products, expecting significant revenue and profit impacts in Q4 2014 due to distributor inventory drawdown.
- 7Cash and cash equivalents stood at $292.7 million as of September 30, 2014, with $324.0 million in remaining borrowing availability under its credit facility.